<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597519</url>
  </required_header>
  <id_info>
    <org_study_id>06-014</org_study_id>
    <secondary_id>CA23766</secondary_id>
    <nct_id>NCT00597519</nct_id>
    <nct_alias>NCT00388102</nct_alias>
  </id_info>
  <brief_title>A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy</brief_title>
  <official_title>A Myeloablative Conditioning Regimen Consisting of Cyclophosphamide, Fludarabine and Total Body Irradiation Followed by the Transplantation of Unrelated Donor Double Unit Umbilical Cord Blood Grafts for Patients With Hematological Malignancy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      In this study two cord blood collections will be used to increase the number of cord blood
      cells you will receive on transplant day. We call this a &quot;double unit&quot; cord blood transplant.
      A previous study suggests double unit cord blood transplant may have a better result. The
      main purpose of this study is to find out how good a cord blood transplant using two cord
      blood collections from two different babies is at curing you of your cancer. Double unit cord
      blood transplants are now being studied as a way to increase the number of cord blood cells
      given to bigger children and adult patients.

      Based on studies that have already been done double unit cord blood transplant appears to be
      safer than if only one cord blood unit is used. However, double unit cord blood transplant is
      a fairly new form of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm phase 2 study to obtain a preliminary estimate of efficacy of
      myeloablative double unit umbilical cord blood transplantation (UCBT) as measured by overall
      and disease-free survival at 1 year post transplantation. The UCB graft will consist of two
      (or double) units from two unrelated newborn donors. Patients with hematopoietic malignancy
      at high-risk for relapse or with advanced disease will receive myeloablative conditioning
      with cyclophosphamide (Cy),low dose fludarabine (Flu) and total body irradiation (TBI) with
      post transplantation cyclosporine (CSA) and mycophenolate mofetil (MMF) for GVHD prophylaxis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response</measure>
    <time_frame>1 year</time_frame>
    <description>To obtain a preliminary estimate of efficacy of double unit UCBT as measured by overall response.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hematopoietic malignancy at high-risk for relapse or with advanced disease will receive myeloablative conditioning with cyclophosphamide (Cy), low dose fludarabine (Flu) and total body irradiation (TBI) with post transplantation cyclosporine (CSA) and mycophenolate mofetil (MMF) for GVHD prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, Cyclophosphamide</intervention_name>
    <description>Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.
Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).
Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transplantation</intervention_name>
    <description>The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 4 - 50 years

          -  Patient should not have a related or unrelated volunteer donor that is suitably HLA
             matched and available in the required time period or be a suitable candidate for an
             autologous stem cell transplant.

          -  Patients will have one of the following hematological malignancies: Acute myelogenous
             leukemia (AML):

               -  Complete first remission (CR1) at high risk for relapse as defined by:

        known prior diagnosis of myelodysplasia (MDS); or therapy related AML; or White cell count
        at presentation &gt; 100,000; or Presence of extramedullary leukemia at diagnosis; or
        Unfavorable FAB type (M0, M5-7); or High-risk cytogenetics (such as those associated with
        MDS, abnormalities of 5, 7, 8, Philadelphia chromosome, complex karyotype); or High risk
        molecular markers such as FLT3 mutations; or Requirement for 2 or more inductions to
        achieve CR1

          -  Complete second CR (CR2).

             • Acute lymphoblastic leukemia (ALL):

          -  Complete first remission (CR1) at high risk for relapse as defined by:

        White cell count at presentation as follows:

          -  &gt; 100,000 if &lt; 18 years

          -  &gt; 50,000 if &gt; 18 years; or

        Presence of extensive extra-medullary disease (excluding CNS disease); or Presence of
        high-risk cytogenetic abnormality such as t(9;22), t(1;19), t(4;11) or other MLL
        rearrangements (11q23), t(8;14) [excluding B-ALL in pediatric patients]; or

        Failed to achieve complete remission after four weeks of induction therapy Unable to
        receive required consolidation chemotherapy as would be needed to maintain remission

          -  Complete second or third remission (CR2 or CR3)

               -  Acute undifferentiated leukemia (AUL), infant leukemia, or biphenotypic leukemia
                  in CR1, CR2 or CR3. Patients with infant leukemia must be eligible to receive
                  total body irradiation.

               -  Juvenile Myelomonocytic leukemia (JMML) with &lt; 30% bone marrow blasts.

               -  Chronic myelogenous leukemia (CML)

          -  GleevecTM failure in 1st or 2nd chronic phase;

          -  Gleevec failure in 1st or 2nd accelerated phase.

             • Myelodysplastic Syndrome (MDS) with one of the following:

          -  Low (Score 0) International Prognostic Scoring System (IPSS) score with
             Life-threatening cytopenia(s); or Red cell or platelet transfusion dependent

          -  Intermediate (Score 1) or High (Score 2) International Prognostic Scoring System
             (IPSS) score.

          -  Patients with bone marrow blasts &gt; 10% should have AML induction therapy with disease
             response to &lt; 5% blasts and at least partial count recovery.

             • Non-Hodgkin's Lymphoma

          -  Patients with high-grade disease following initial therapy and are not appropriate for
             further chemotherapy or autologous stem cell transplantation.

          -  Patients with high-grade or diffuse large cell NHL with recurrent disease after first
             remission and must have:

        Chemo-sensitivity as evidenced by &gt; partial remission (PR) (defined as &gt; 50% reduction in
        mass size after therapy).

          -  Patients with adequate organ function and performance status criteria as measured by:

          -  Karnofsky score &gt; or = to 70 % or Lansky score &gt; or = to 70%

          -  Renal: Calculated creatinine clearance &gt; or = to 60 ml/min

          -  Hepatic: Total bilirubin &lt; 2.5 mg/dL unless benign congenital hyperbilirubinemia
             (Gilbert's syndrome) and ALT/AST &lt; 3 x upper limit of normal

          -  Albumin &gt; or = to 2.5

          -  Pulmonary: Pulmonary function (spirometry and corrected DLCO) &gt; or = to 60% normal if
             available (in small children use History and Physical and CT scan as necessary to
             determine pulmonary status)

          -  Cardiac: Left ventricular ejection fraction &gt; or = to 50%

          -  Double Unit Umbilical Cord Blood Grafts:

        Units will be selected based on the HLA match to the patient and on the basis of the
        individual and combined cell doses of the units.

          -  Patient has a related or unrelated volunteer donor that is suitably HLA matched and
             available in the required time period.

          -  Patient is a candidate for an autologous stem cell transplant.

          -  Active CNS leukemia.

          -  Acute Myelogenous Leukemia in greater than CR2.

          -  Acute Myelogenous Leukemia evolved from myelofibrosis.

          -  Acute Lymphoblastic Leukemia, acute undifferentiated leukemia, biphenotypic leukemia
             or infant leukemia greater than CR3.

          -  Any acute leukemia with:

               -  Morphologic relapse or persistent disease in the BM (cytogenetic relapse without
                  morphologic evidence of relapse or cytogenetic persistent disease in the BM is
                  acceptable); or

               -  Active extra-medullary leukemia; or

               -  Requiring greater than 2 cycles of chemotherapy to obtain present remission
                  status;

          -  Bone Marrow aplasia (defined as BM cellularity less than 5% at transplant work-up); or

          -  MDS with greater than 10% bone marrow blasts refractory to chemotherapy; or

          -  CML in blast crisis; or

          -  NHL refractory to chemotherapy (less than PR after 2 or more regimens); or

          -  Prior autologous or allogeneic HSC transplant at any time; or

          -  Prior radiation therapy rendering patient ineligible for TBI; or

          -  Uncontrolled viral, bacteria or fungal infection at time of study enrollment; or

          -  Seropositive or NAT positive for HIV; or

          -  Females who are pregnant or breast feeding; or

          -  Patient or guardian unable to give informed consent or unable to comply with the
             treatment protocol including appropriate supportive care, follow-up, and research
             tests.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliet Barker, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering web site</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2008</study_first_posted>
  <results_first_submitted>January 14, 2016</results_first_submitted>
  <results_first_submitted_qc>January 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2016</results_first_posted>
  <last_update_submitted>January 14, 2016</last_update_submitted>
  <last_update_submitted_qc>January 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Total Body Irradiation</keyword>
  <keyword>Umbilical Cord Blood Grafts</keyword>
  <keyword>06-014</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Cyclophosphamide, Fludarabine and Total Body Irradiation Followed by the Transplantation of Unrelated Donor Double Unit Umbilical Cord Blood Grafts for Patients with Hematological Malignancy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Cyclophosphamide, Fludarabine and Total Body Irradiation Followed by the Transplantation of Unrelated Donor Double Unit Umbilical Cord Blood Grafts for Patients with Hematological Malignancy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response</title>
        <description>To obtain a preliminary estimate of efficacy of double unit UCBT as measured by overall response.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Cyclophosphamide, Fludarabine and Total Body Irradiation Followed by the Transplantation of Unrelated Donor Double Unit Umbilical Cord Blood Grafts for Patients with Hematological Malignancy</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response</title>
          <description>To obtain a preliminary estimate of efficacy of double unit UCBT as measured by overall response.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Cyclophosphamide, Fludarabine and Total Body Irradiation Followed by the Transplantation of Unrelated Donor Double Unit Umbilical Cord Blood Grafts for Patients with Hematological Malignancy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term- Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term- Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term-Disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Glucose, high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Magnesium, high (hypermagnesemia)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Phosphate, low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Potassium, high (hyperkalemia)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Potassium, low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sodium, low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Juliet Barker</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>212-639-3468</phone>
      <email>barkerj@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

